查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587504

抗菌素抗药性诊断市场规模、份额、趋势分析报告：按技术、最终用途、病原体、地区、细分市场预测，2025-2030 年

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microbiology Culture, PCR), By End-use (Hospitals, Diagnostic Laboratories), By Pathogen, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

抗生素抗药性诊断市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球抗菌药物抗药性诊断市场规模预计将达到67亿美元，2025年至2030年复合年增长率为6.55%。

抗药性病菌感染的风险不断增加，特别是在医疗机构中，以及政府和非政府组织加强应对抗菌素抗药性威胁，是推动市场成长的关键因素。此外，主要市场参与者为管理抗菌素抗药性所采取的各种策略倡议也有助于市场扩张。例如，2021年3月，生物梅里埃与GIZ联合支持尼日利亚疾病管制中心加强对抗抗菌素抗药性。

由于越来越多地采用快速检测和 PoC 检测来检测抗药性细菌感染疾病，预计该市场将在预测期内扩大。此外，丹纳赫和雅培等领先的市场参与者拥有强大的抗生素抗药性病菌感染快速诊断测试产品系列。此外，AMR 行业联盟等非政府组织的日益参与正在帮助监管机构制定策略，促进诊断解决方案的开发，以管理抗菌素抗药性。

增加用于开发用于诊断抗菌药物抗药性感染疾病的新型自动化测试解决方案的资金筹措预计将在预测期内推动市场成长。例如，2022年5月，欧洲投资银行向POCARED Diagnostics提供超过2,400万美元资金，用于微生物疾病全自动检测的研发。 POCARED Diagnostics 参与开发新的微生物测试，可在数小时内提供结果。

预计未来几年抗菌药物抗药性将会增加。因此，为了有效管理和监测抗菌药物抗药性的进展，对准确、快速检测方案的需求预计将会增加。据CDC称，美国每年因抗菌药物抗药性造成的直接医疗费用约为200亿美元。

新兴市场的主要参与者正在不断努力开拓新的测试，以巩固其市场地位。此外，主要企业也采取收购、联盟、合作等其他策略来扩大产品系列。例如，2022 年 8 月，Accelerate Diagnostics 和 BD 宣布合作应对抗菌素抗药性的威胁。透过这项协议，BD 将向 Accelerate Diagnostics 庞大的客户群提供抗生素相关抗药性的快速诊断解决方案。

抗菌素抗药性诊断市场报告亮点

  • PCR领域占市场主导地位，2024年收益占有率最大，为24.19%。 PCR 技术的进步及其由于其高精度而广泛采用，是推动该细分市场占据较大份额的主要因素。
  • 2024年，抗药性金黄色葡萄球菌细分市场占据最大市场占有率，达28.33%。医院环境中 MRSA 发生率的增加是该细分市场扩张的主要驱动力。
  • 2024年，医院细分市场领先，占销售份额的48.07%。此细分市场的成长受到多种因素的推动，包括医院感染发生率上升以及抗菌素抗药性 (AMR) 感染导致的住院人数增加。
  • 北美抗菌素抗药性诊断市场在全球整体市场中占据主导地位，2024年收益占有率为42.03%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章抗菌素抗药性诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 抗菌素抗药性诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章抗生素抗药性诊断市场：技术估算与趋势分析

  • 细分仪表板
  • 抗生素抗药性诊断市场：技术变化分析
  • 抗菌素抗药性诊断市场：技术展望
  • 2018-2030年市场规模、预测及趋势分析
  • 微生物学培养
  • 免疫检测
    • PCR
    • 下一代种子
    • 质谱分析
    • 快速照护现场
    • 其他的

第五章抗菌药物抗药性诊断市场：按病原体估计和趋势分析

  • 细分仪表板
  • 抗菌药物抗药性诊断市场：病原体变异分析
  • 按病原体分類的抗生素抗药性诊断市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 抗药性肺炎链球菌 (DRSP)
  • 抗药性弯曲曲状桿菌(DRC)
  • 困难梭状芽孢桿菌(CD)
  • 抗药性淋病 (DRNG)
  • 抗药性沙门氏菌 (DRNTS)
  • 其他的

第六章抗菌素抗药性诊断市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 抗菌素抗药性诊断市场：最终用途变异分析
  • 按最终用途分類的抗菌素抗药性诊断市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 医院
  • 诊断实验室
  • 製药和生物技术公司
  • 其他的

第七章抗生素抗药性诊断市场：区域估计与趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 市场参与企业分类
  • 主要市场参与企业的最新趋势和影响分析
  • 2024 年企业市场占有率分析
  • 主要企业简介
    • bioMerieux
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • BD
    • Danaher
    • Accelerate Diagnostics, Inc.
    • Molsid
    • Vela Diagnostics
    • Visby Medical, Inc.
    • Hologic, Inc.
Product Code: GVR-4-68039-990-4

Antimicrobial Resistance Diagnostics Market Growth & Trends:

The global antimicrobial resistance diagnostics market size is expected to reach USD 6.70 billion by 2030, registering a CAGR of 6.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies' efforts to combat the threat of AMR are the major factor contributing to market growth. In addition, various strategic initiatives undertaken by leading market players to manage antimicrobial resistance are also contributing to market expansion. For instance, in March 2021, bioMerieux and GIZ collaborated to support the Nigerian center for disease control to strengthen the fight against AMR.

The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated to augment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfolio of rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies to make strategies to boost the development of diagnostic solutions to manage antimicrobial resistance.

Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated to boost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million to POCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.

Antimicrobial resistance is expected to rise in the coming years. Hence, demand for accurate & fast testing options is expected to increase for the effective management and progression monitoring of antimicrobial resistance. According to the CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.

Key market players are continuously involved in the development of novel tests to strengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are also adopted by leading players to expand their product portfolio in different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration to combat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance to its vast customers.

Antimicrobial Resistance Diagnostics Market Report Highlights:

  • The PCR segment dominated the market and accounted for the largest revenue share of 24.19% in 2024. Advancements in PCR technology, along with its widespread adoption due to its high accuracy, are key factors driving the significant share of this segment.
  • In 2024, the methicillin resistant staphylococcus aureus segment held the largest market share at 28.33%. The rising incidence of MRSA in hospital settings is a key driver for the expansion of this segment.
  • In 2024, the hospitals segment led the market, accounting for 48.07% of the revenue share. The growth of this segment is driven by several factors, including the rising incidence of hospital-acquired infections and increased hospitalizations due to antimicrobial-resistant (AMR) infections, which often lead to prolonged hospital stays.
  • North America antimicrobial resistance diagnostics market dominated the overall global market with a revenue share of 42.03% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Pathogen
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Antimicrobial Resistance Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in risk of developing drug - resistant bacterial infections
      • 3.2.1.2. Introduction of novel technologies to diagnose AMR infections
      • 3.2.1.3. Favorable government initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
  • 3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Antimicrobial Resistance Diagnostics Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
  • 4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Microbiology Culture
    • 4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Immunoassay
    • 4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. PCR
      • 4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. NGS
      • 4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Mass Spectrometry
      • 4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Rapid & Point of Care
      • 4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Antimicrobial Resistance Diagnostics Market: Pathogen Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
  • 5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
    • 5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Drug Resistant Campylobacter (DRC)
    • 5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Clostridium Difficile (CD)
    • 5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Drug Resistant Neisseria Gonorrhoeae (DRNG)
    • 5.8.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Drug Resistant Salmonella (DRNTS)
    • 5.9.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Antimicrobial Resistance Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
  • 6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Pharmaceutical & Biotechnology Companies
    • 6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antimicrobial Resistance Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. bioMerieux
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. F. Hoffmann - La Roche Ltd
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Abbott
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. BD
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Danaher
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Accelerate Diagnostics, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Molsid
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Vela Diagnostics
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Visby Medical, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Hologic, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 4 Global Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 5 Global Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Antimicrobial Resistance Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 8 North America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 9 North America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 11 U.S Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 12 U.S Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Mexico Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 14 Mexico Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 15 Mexico Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Canada Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 17 Canada Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 18 Canada Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 21 Europe Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 22 Europe Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 UK Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 24 UK Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 25 UK Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Germany Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 27 Germany Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 28 Germany Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 29 France Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 30 France Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 31 France Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 32 Italy Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 33 Italy Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 34 Italy Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 36 Spain Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 37 Spain Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 39 Denmark Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 40 Denmark Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 41 Norway Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 42 Norway Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 43 Norway Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Sweden Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 45 Sweden Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 46 Sweden Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Japan Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 52 Japan Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 53 Japan Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 China Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 55 China Antimicrobial Resistance Diagnostics market, by Pathogen 2018 - 2030 (USD Million)
  • Table 56 China Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 57 India Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 58 India Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 59 India Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Australia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 61 Australia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 62 Australia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 South Korea Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 64 South Korea Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 65 South Korea Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 67 Thailand Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 68 Thailand Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 71 Latin America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 72 Latin America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 74 Brazil Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 75 Brazil Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 77 Argentina Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 78 Argentina Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 84 South Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 85 South Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 90 UAE Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 91 UAE Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Antimicrobial Resistance Diagnostics market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Antimicrobial resistance diagnostics market, Technology outlook key takeaways, 2024 & 2030 (USD Million)
  • Fig. 12 Antimicrobial resistance diagnostics market: Pathogen movement analysis, 2024 & 2030 (USD Million)
  • Fig. 13 Antimicrobial resistance diagnostics market: end use movement analysis, 2024 & 2030 (USD Million)
  • Fig. 14 Microbiology Culture market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Immunoassay market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 PCR market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 NGS market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Mass Spectrometry market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Rapid & Point of Care market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Drug Resistant Streptococcus Pneumoniae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Drug Resistant Campylobacter market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Clostridium Difficile market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Methicillin Resistant Staphylococcus Aureus market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Drug Resistant Neisseria Gonorrhoeae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Drug Resistant Salmonella market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Hospitals market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Diagnostic Laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Pharmaceutical & Biotechnology Companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 North America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 US antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Europe antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 UK antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Germany antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 France antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 India antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Australia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 List of key emerging company's/Allergen disruptors/innovators